Annotation Detail

Information
Associated Genes
FCGR3A
Associated Variants
FCGR3A p.Phe176Val (p.F176V) ( ENST00000367967.8, ENST00000436743.7, ENST00000699395.1, ENST00000699397.1, ENST00000699399.1, ENST00000699401.1, ENST00000699396.1, ENST00000426740.8, ENST00000699400.1, ENST00000443193.6, ENST00000699398.1 )
FCGR3A p.Phe176Val (p.F176V) ( ENST00000367967.8, ENST00000426740.8, ENST00000436743.7, ENST00000443193.6, ENST00000699395.1, ENST00000699396.1, ENST00000699397.1, ENST00000699398.1, ENST00000699399.1, ENST00000699400.1, ENST00000699401.1 )
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survival between trastuzumab-treated patients who had the FCGR3A 158 V/V high-affinity genotype and patients without that genotype (V/F and F/F).
Variant Origin
Common Germline
Variant Origin
Common Germline
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1087
Gene URL
https://civic.genome.wustl.edu/links/genes/1844
Variant URL
https://civic.genome.wustl.edu/links/variants/457
Rating
4
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Does Not Support
Drug
Trastuzumab
Evidence Level
B
Clinical Significance
N/A
Pubmed
24989892
Drugs
Drug NameSensitivitySupported
TrastuzumabN/Afalse